In this PACULit episode, Britany and Seth discuss the Turkish Oncology Group’s TOG study, a multicenter retrospective cohort of 153 patients with metastatic gastric or GEJ adenocarcinoma and PD-L1 CPS ≥5 treated with first-line nivolumab plus chemotherapy. The discussion covers study design, key outcomes (median PFS 11.06 months; median OS 16.03 months), and the prognostic and predictive value of baseline systemic inflammatory markers (NLR, PLR, SII). It highlights that SII and PD-L1 CPS independently predict treatment response, while NLR and PLR are significant only in univariate analyses, and notes limitations such as retrospective design and baseline-only measurements. The episode also discusses clinical implications for using SII alongside PD-L1 CPS to refine patient selection and monitoring, plus future directions like prospective dynamics, broader populations, and integration with genomic or microbiome data.
View all episodes
